Lv3
330 积分 2024-06-30 加入
Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study
3天前
已完结
Furmonertinib: First Approval
8天前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
9天前
已完结
Furmonertinib: First Approval
1个月前
已完结
Stemness in solid malignancies: coping with immune attack
1个月前
已完结
Immunoproteasome as a biomarker for immunotherapy
1个月前
已完结
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study
1个月前
已完结
A standing platform for cancer drug development using ctDNA-based evidence of recurrence
1个月前
已完结
Targeting therapy-persistent residual disease
1个月前
已完结
Two decades of advances in clinical oncology — lessons learned and future directions
1个月前
已完结
皖公网安备34019202002308
